NCT01539473

A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

A Phase 1, Blinded, Placebo-Controlled, Crossover TR-701 FA Study of Blood Pressure Response Post-Tyramine Challenge

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Phase 1 study to determine the effect of oral TR-701 FA on SBP response when administered with tyramine

Detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled, 2-way crossover study to determine the effect of 200 mg oral TR-701 FA on SBP response when administered with tyramine in healthy adult male and female volunteers.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	TR-701 FA with Tyramine	TR-701 FA 200 mg oral and Tyramine
DRUG	Placebo-controlled withTyramine	Placebo-controlled and Tyramine

Timeline

• Start date: 2012-02-01
• Primary completion: 2012-05-01
• Completion: 2012-05-01
• First posted: 2012-02-27
• Last updated: 2016-05-03

Locations

1 site across 1 country: United States